Abstract
Background A 54-year-old man with a 22-year history of rheumatoid arthritis and an 8-year history of chronic obstructive pulmonary disease presented with dyspnea on exertion, nonproductive cough and fatigue of 1 month's duration. His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol.
Investigations At presentation, the patient underwent physical examination, chest X-ray and high-resolution CT, blood tests, and bronchoalveolar lavage fluid analysis including auramine stains and gene sequence analysis of cultured Mycobacterium szulgai. The patient underwent minithoracotomy after 6 months, and bronchoalveolar lavage fluid analysis, culture and chest X-ray after 18 months. Further chest imaging and culture of sputum samples were performed another year later.
Diagnosis Pulmonary M. szulgai infection.
Management Triple drug therapy with rifampicin, ethambutol hydrochloride and clarithromycin. Anti-tumor necrosis factor treatment was continued.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
American Thoracic Society (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 156: S1–S25
Zhang Q et al. (2002) Pseudoepidemic due to a unique strain of Mycobacterium szulgai: genotypic, phenotypic, and epidemiological analysis. J Clin Microbiol 40: 1134–1139
Jeong YJ et al. (2004) Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology 231: 880–886
Ishige I et al. (1999) Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354: 120–123
Doty JD et al. (2005) Treatment of sarcoidosis with infliximab. Chest 127: 1064–1071
Gonzalez-Lopez MA et al. (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55: 817–820
Saliu OY et al. (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194: 486–492
Gardam MA et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148–155
Wallis RS et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261–1265
Mufti AH et al. (2005) Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α use. Diagn Microbiol Infect Dis 53: 233–238
Phillips K et al. (2002) Experience with etanercept in an academic medical centre: are infection rates increased? Arthritis Rheum 47: 17–21
Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41: 201–208
Garcia Vidal C et al. (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756–759
Matsumoto T (2006) Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 355: 740–741
Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society (2000) Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55: 210–218
Benator DA et al. (1997) Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Am J Med Sci 313: 346–351
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
van Ingen, J., Boeree, M., Janssen, M. et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Rev Rheumatol 3, 414–419 (2007). https://doi.org/10.1038/ncprheum0538
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0538
This article is cited by
-
Risk factors for nontuberculous mycobacterial pulmonary disease (NTM-PD) in Croatia
Wiener klinische Wochenschrift (2021)
-
Treatment of Non-Tuberculous Mycobacterial Lung Disease
Current Treatment Options in Infectious Diseases (2016)
-
Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy
Nature Reviews Rheumatology (2013)
-
Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection?
Clinical Rheumatology (2012)
-
Nontuberculous Mycobacteria and the Lung: From Suspicion to Treatment
Lung (2010)